Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People who have been diagnosed with multiple myeloma (a type of blood cancer) according to standard international diagnostic guidelines
- People whose multiple myeloma has come back after treatment (relapsed) or has stopped responding to treatment (refractory)
- People whose disease previously responded, at least partially, to one or more prior treatments
- People whose multiple myeloma has shown signs of getting worse during or after their most recent treatment
Who may not be able to join:
- People who have previously received daratumumab or any other treatment that specifically targets a protein called CD38
- People whose myeloma did not respond to, or who could not tolerate, a medication called lenalidomide
- People who, in the trial doctor's opinion, may not be able to follow the study procedures — for example, due to a psychological condition — or for whom joining the trial would not be in their best interest or could affect their wellbeing (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82 32 850 5727
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PK equivalence of CT-P44 and Darzalex Faspro; Therapeutic equivalence of CT-P44 and Darzalex Faspro
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.